Bayer HealthCare collaborates with Sysmex Inostics

Published: 9-Oct-2013
Analysis

To develop blood-based companion diagnostic tests for targeted tumour therapies


Bayer Healthcare is to collaborate with Sysmex Inostics, based in Hamburg, Germany, a division of Sysmex Corporation of Japan, to develop blood-based companion diagnostic tests in oncology, opening up new possibilities in personalised medicine.

Companion diagnostic tests analyse the specific molecular characteristics of a patient’s cancer tumour to help guide treatment decisions. The tests will provide evidence of which patients are more likely to respond to a particular anti-cancer agent.

Under the agreement, Sysmex Inostics will develop blood-based diagnostic tests based on its BEAMing technology, which enables a very sensitive analysis of circulating DNA shed into the blood stream from tumours and provides a non-invasive alternative to biopsies to obtain the mutational status of a patient’s tumour. This 'liquid biopsy' allows the selection of an appropriate therapeutic agent without the need of further surgeries or biopsies. Moreover, blood-based diagnostic DNA tests can be performed on patients where no tumour tissue is available.

  • Companies:
  • Bayer
  • Sysmex Corporation
See more

You may also like

Media

TissUse establishes a multi-organ model for risk assessment with Bayer

Read more
The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay

Trending Articles

  1. Fluidic Sciences relaunches Microfluidic Diffusional Sizing technology to refine protein-protein interaction analysis The Microfluidic Diffusional Sizing (MDS) technology allows scientists better options when characterising a protein's biophysical properties
  2. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  3. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  4. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  5. How microfluidic diffusional sizing can enhance your protein assays MDS can enhance the information gained from an assay experiment and allow the timely and guided production of novel protein and antibody-based therapeutics

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Media

TissUse establishes a multi-organ model for risk assessment with Bayer

The biotechnology company has signed a collaboration agreement with the pharmaceutical and life sciences company to develop a liver-endocrine tissue assay
Manufacturing

A world of difference

Most companies now boast a sustainability strategy. Hilary Ayshford summarises some of the latest thinking in the pharmaceutical manufacturing sector
Manufacturing

SEMOFS project needs more work, partners say

<p>The partners in the Surface Enhanced Micro Optical Fluidic Systems (SEMOFS) project are currently discussing the possibilities for further cooperation and follow-up projects.</p>
Research & Development

Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research

The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
Manufacturing

Supporting accurate high-pressure flow measurement with Titan's Oval Gear liquid flow meters

The Oval Gear liquid flow meter is built to perform in extreme conditions, and can be customised to a range of industries, including aerospace, mining, marine, automotive and oil & gas
Research & Development

Concept and Accelero Biostructures accelerate early drug discovery with X-ray crystallography

The companies will incorporate their X-ray crystallography and drug discovery technologies to offer clients rapid hit-to-lead drug development
Research & Development

Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility

The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
Subscribe now